Sign in

    Jeannie Kim

    Research Analyst at BTIG

    Jeannie Kim is an analyst at BTIG with a focus on equity research, known for her sector expertise and analytical rigor, though specifics about her exact title, company coverage, and performance metrics are not publicly detailed. While her professional presence suggests coverage of dynamic industries, there is no direct evidence of ranked performance, TipRanks ratings, or published returns. Her accessible online career record does not include a visible timeline, prior firms, or confirmatory records of securities registrations or licenses. Due to limited publicly available information, further details about her professional credentials and notable achievements remain unavailable.

    Jeannie Kim's questions to Stoke Therapeutics (STOK) leadership

    Jeannie Kim's questions to Stoke Therapeutics (STOK) leadership • Q2 2025

    Question

    Jeannie Kim, on behalf of Tom Schroeder from BTIG, asked about the rationale for advancing STK-002 into clinical development for ADOA at this time and requested details on the key non-human primate (NHP) data that supported the decision.

    Answer

    Interim CEO Ian Smith stated the decision was triggered by compelling NHP data showing potential vision improvement. CMO Barry Ticho elaborated that in a naturally occurring monkey model of ADOA, STK-002 demonstrated improvements in both mitochondrial function (measured by FPF) and optic nerve function (measured by ERG), providing strong confidence to proceed to human trials.

    Ask Fintool Equity Research AI